Actively Recruiting

Age: 18Years +
All Genders
NCT06154668

Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients

Led by University Hospital, Grenoble · Updated on 2024-02-20

707

Participants Needed

1

Research Sites

363 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Grenoble

Lead Sponsor

E

Etablissement Français du Sang

Collaborating Sponsor

AI-Summary

What this Trial Is About

Despite being standard of care, there are still many medical requirements related to immune checkpoint blocker based therapies such as identify patients susceptible to respond with the less adverse events, evaluate the clinical benefit of adjuvant treatment /risk of relapse and design new strategies for non-responder patients. Thus, this project aims at understanding the impact of anti-PD1 on the immune system through investigation of the phenotypic, functional, metabolic and transcriptomic profiles of circulating DC subsets and effectors in response to anti-PD1 therapy in melanoma patients. The primary objective of the study is to identify the biomarkers of response to anti-PD1 according to the type of patient before the start of the treatment.

CONDITIONS

Official Title

Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient with histologically confirmed melanoma (stage I, II, III or IV based on AJCC classification)
  • Able to sign the informed collection consent for the retrospective part or to express their non-opposition to the research for the prospective part of the study
Not Eligible

You will not qualify if you...

  • Subject under guardianship or subject deprived of freedom
  • Persons benefiting from special protection such as minors, pregnant or breastfeeding women, adults protected by law (under guardianship, curatorship or deprived of liberty), and persons hospitalized without their consent
  • Ocular melanoma

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CHU Grenoble Alpes

Grenoble, France, 38043

Actively Recruiting

Loading map...

Research Team

J

Julie Charles, MD, PhD

CONTACT

S

Stéphane Mouret, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here